13 results about "Polyinosinic Acids" patented technology

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The invention relates to the technical field of cell culture, and provides an NK cell in-vitro amplification culture method which comprises the following steps: S1, separating to obtain a mononuclear cell of peripheral blood, resuspending the mononuclear cell by using a serum-free NK cell basic culture medium, and then inoculating the mononuclear cell to an NK cell activation culture medium for incubation; s2, culturing to the third day, supplementing the NK cell to activate the culture medium for amplification, then supplementing the NK cell to activate the culture medium once every other day, and culturing to the 19th day to obtain high-purity NK cells; the NK cell activation culture medium is a serum-free NK cell basal culture medium which contains IL-2 (Interleukin-2), IL-12 (Interleukin-12), IL-18 (Interleukin-18), IL-21 (Interleukin-21), a CD16 antibody, a CD56 antibody, 4-1BBL (4-1BBL), nicotinamide, sodium diethyldithiocarbamate, polyinosinic acid and plasma. The method is simple and convenient to operate and short in culture period, the amplification efficiency reaches up to 1050 times within 19 days, and the NK cells are high in purity and accord with clinical treatment standards.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

The invention discloses a veterinary epidemic prevention medicine as well as a preparation method and application thereof, and relates to the field of veterinary drug research and development and veterinary medicine, and the veterinary epidemic prevention medicine is prepared from the following components in parts by volume: 9.0-9.8 parts of Shuanghuanglian; 0.2 to 1.0 part of polyinosinic cell; through the molecular chaperone effect of the Shuanghuanglian and the polyinosinic-polycytidylic acid, the permeability and retention of the antiviral drug in myocardial tissues are remarkably improved, the technical bottleneck that a traditional drug is insufficient in myocardial virus load control is broken through, the damage of cytokine storm to myocardial cells is effectively inhibited while the antiviral immune response is enhanced, and the curative effect is good. The ratio of the Shuanghuanglian to the polyinosinic acid is optimized, the basic antiviral activity of the Shuanghuanglian is guaranteed, the immune regulation function of the polyinosinic acid is exerted with the minimum effective dose, the dose-dependent side effect is avoided, the medication process is simplified in clinical application, an innovative medicine combination with high efficiency, safety and economical efficiency is provided for the modern breeding industry, and the clinical application prospect is wide. And the method has remarkable industrial popularization value.

The present invention discloses a pharmaceutical composition, its manufacturing method, and its use, wherein the pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient, the first active ingredient being a microbial agent containing one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, or Salmonella paratyphi, and the second active ingredient comprising polyinosinic acid, polycytidylic acid, and vitamins. The pharmaceutical composition is an artificial active immunotherapy for tumors, which, by "stimulating" the entire immune system, activates the human immune system using bacteria to kill cancer cells, making the treatment extremely stable and reliable, significantly saving and extending the lives of cancer patients, while simultaneously being extremely safe, having very few toxic side effects, and having low manufacturing costs.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and polyinosinic acid combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment by regulating and controlling the antigen presentation function of cDC1, and the treatment effect of polyinosinic-cytidylic acid is improved. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and polyinosinic-cytidylic acid can better inhibit tumor growth, can effectively promote CD8 + T cell infiltration in tumors, has more cDC1 infiltration in tumor tissues, shows a stronger inhibition effect on tumors, and can be used for preparing drugs for treating tumors. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.

The invention provides application of a polyinosinic-polycytidylic acid combined water-in-oil adjuvant in preparation of animal vaccines or animal virus antiserum, and belongs to the technical field of animal virology. The invention provides application of a polyinosinic-polycytidylic acid combined water-in-oil adjuvant in preparation of animal vaccines or animal virus antiserum. According to the invention, the polyinosinic acid is used as the immunopotentiator and is matched with the water-in-oil adjuvant, so that the immune effect can be remarkably enhanced, and compared with a group without the polyinosinic acid, the titer of a neutralizing antibody of the prepared serum is increased by 3-4 times. The invention also provides a preparation method of the virus positive serum. According to the invention, the inactivated antigen prepared by the polyinosinic-polycytidylic acid combined with the water-in-oil adjuvant and the active virus antigen are used for alternative immunization, so that the titer of a neutralizing antibody can be improved by more than 10 times; the prepared virus positive serum can fully meet the requirements of product quality control on an inspection reagent in the aspects of titer and specificity.

Disclosed are pharmaceutical compositions formulated from immunomodulators formed from glycogen nanoparticles, such as monodisperse phytoglycogen nanoparticles, complexed with a pattern recognition receptor agonist, such as a TLR agonist which can be poly I:C. Also disclosed are methods of treating solid tumor cancers using the described immunomodulators, and uses of the immunomodulators to treat solid tumor cancers and to manufacture medicaments to treat solid tumor cancers.

The invention belongs to the technical field of biological medicines, and particularly discloses a DC cell-based tumor vaccine and a preparation method thereof, and the preparation method comprises the following steps: (1) separating peripheral blood to prepare a mononuclear cell suspension; (2) inoculating the mononuclear cell suspension into a first culture medium, culturing for 48-72 hours, then replacing 40-60% of the first culture medium every 48-72 hours, and continuing culturing to obtain a first cell sap; (3) preparing the tumor tissue into a cell lysate; and (4) adding the cell lysate, polyinosinic-cytidylic acid, TNF-alpha and alpha-ketoglutaric acid into the first cell sap, and carrying out co-culture to obtain the DC cell-based tumor vaccine. The DC cell-based tumor vaccine prepared by the method provided by the invention can specifically kill tumor cells.

The present invention relates to compositions comprising particles, each of said particles comprising a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid [poly(IC)], and at least one linear polyal-kyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to the use of said compositions as medicaments, in particular for the treatment of a cell growth disorder characterized by abnormal growth of human or animal cells, as well as to processes for the preparation of said compositions.